- Investing.com
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Molbreevi's Promise | Savara's lead candidate for rare respiratory disease aPAP shows strong potential, with a completed BLA submission and high approval probability |
Market Opportunity | Discover how a larger-than-expected patient population could drive Molbreevi to potential blockbuster status, with peak sales projections exceeding $1 billion |
Financial Fortitude | Explore Savara's robust financial position, with $173 million in cash and a debt financing deal providing runway into 2027 and supporting commercialization efforts |
Analyst Optimism | Delve into analyst perspectives, with price targets around $9.00, reflecting confidence in Molbreevi's approval prospects and commercial potential |
Metrics to compare | SVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSVRAPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.4x | −4.5x | −0.5x | |
PEG Ratio | 0.17 | 0.02 | 0.00 | |
Price/Book | 3.7x | 3.1x | 2.6x | |
Price / LTM Sales | - | 192.5x | 3.2x | |
Upside (Analyst Target) | 184.6% | 167.9% | 42.0% | |
Fair Value Upside | Unlock | 8.1% | 6.6% | Unlock |